Perform Another (Advanced) Search

1.  Newly Approved Drug Therapies (703) Remicade (infliximab), Centocor,
...Newly Approved Drug Therapies (703) Remicade (infliximab), Centocor, Drug Information The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Drug Name: Remicade (infliximab) Company: Centocor Approval Status: Approved January 2001 Treatment Area: Rheumatoid arthritis General Information The FDA ...
View Page

2.  Newly Approved Drug Therapies (759) Remicade (infliximab), Centocor,
...Newly Approved Drug Therapies (759) Remicade (infliximab), Centocor, Drug Information The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Drug Name: Remicade (infliximab) Company: Centocor Approval Status: Approved February 2002 Treatment Area: Rheumatoid arthritis General Information Remicade, administered ...
View Page

3.  Study Posting (4843) Trial #117070, Hepatitis C; Chronic, Cleveland, OH
...Study Posting (4843) Trial #117070, Hepatitis C; Chronic, Cleveland, OH Trial Information Infliximab (Remicade®) as an Adjunct to Pegylated-Interferon Alpha 2b and Ribavirin in the Treatment of ...
...found to have high levels of TNFa, a protein that causes inflammation (swelling and irritation). Infliximab is an antibody (a substance the body makes to fight infection) that binds to TNFa ...
View Page

4.  Study Posting (2541) Trial #69187, Crohn's Disease, Egg Harbor Township, NJ
...Egg Harbor Township, NJ Trial Information Do You Have Crohn's Disease? Have You Received Infliximab (Remicade) Therapy? Dr. Barry P. Kaufman and Atlantic Gastroenterology Associates are conducting a clinical Research ...
...moderate to severe Crohn's disease who have lost response to or are intolerant to Infliximab (Remicade). Your participation in this study would last for up to 6 weeks with the ...
View Page

5.  Study Posting (5251) Trial #144108, Rheumatoid Arthritis, Various Cities, United Kingdom
...been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion. The study will be conducted for 30 weeks and will include 200 subjects. All ...
View Page

6.  Study Posting (5251) Trial #144107, Rheumatoid Arthritis, Various Cities, Spain
...been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion. The study will be conducted for 30 weeks and will include 200 subjects. All ...
View Page

7.  Study Posting (5251) Trial #144106, Rheumatoid Arthritis, Various Cities, Netherlands
...been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion. The study will be conducted for 30 weeks and will include 200 subjects. All ...
View Page

8.  Study Posting (5251) Trial #144105, Rheumatoid Arthritis, Various Cities, Israel
...been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion. The study will be conducted for 30 weeks and will include 200 subjects. All ...
View Page

9.  Study Posting (5251) Trial #144104, Rheumatoid Arthritis, Various Cities, Germany
...been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion. The study will be conducted for 30 weeks and will include 200 subjects. All ...
View Page

10.  Study Posting (5251) Trial #144103, Rheumatoid Arthritis, Various Cities, France
...been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion. The study will be conducted for 30 weeks and will include 200 subjects. All ...
View Page

11.  Study Posting (5251) Trial #144102, Rheumatoid Arthritis, Various Cities, Finland
...been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion. The study will be conducted for 30 weeks and will include 200 subjects. All ...
View Page

12.  Study Posting (5251) Trial #144109, Rheumatoid Arthritis, Various Cities, Canada
...been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion. The study will be conducted for 30 weeks and will include 200 subjects. All ...
View Page

13.  Study Posting (5251) Trial #144101, Rheumatoid Arthritis, Various Cities, Austria
...been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion. The study will be conducted for 30 weeks and will include 200 subjects. All ...
View Page

14.  Study Posting (5251) Trial #144081, Rheumatoid Arthritis, Reston, VA
...been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion. The study will be conducted for 30 weeks and will include 200 subjects. All ...
View Page

15.  Study Posting (5251) Trial #144092, Rheumatoid Arthritis, Burke, VA
...been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion. The study will be conducted for 30 weeks and will include 200 subjects. All ...
View Page

16.  Study Posting (5251) Trial #144058, Rheumatoid Arthritis, Tyler, TX
...been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion. The study will be conducted for 30 weeks and will include 200 subjects. All ...
View Page

17.  Study Posting (5251) Trial #144062, Rheumatoid Arthritis, Temple, TX
...been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion. The study will be conducted for 30 weeks and will include 200 subjects. All ...
View Page

18.  Study Posting (5251) Trial #144091, Rheumatoid Arthritis, Mesquite, TX
...been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion. The study will be conducted for 30 weeks and will include 200 subjects. All ...
View Page

19.  Study Posting (5251) Trial #144084, Rheumatoid Arthritis, Houston, TX
...been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion. The study will be conducted for 30 weeks and will include 200 subjects. All ...
View Page

20.  Study Posting (5251) Trial #144098, Rheumatoid Arthritis, Houston, TX
...been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion. The study will be conducted for 30 weeks and will include 200 subjects. All ...
View Page